• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

Buy Stocks You Think Will Survive 'Nuclear Winter'

If you buy right, time and value should do most of the heavy lifting for you.
By TIM MELVIN Jan 18, 2017 | 12:00 PM EST
Stocks quotes in this article: GILD, LEN

I spend a lot of time thinking and tailing about valuation ratio. Buying a business at the right price can help offset many of the usual investing mistakes. As an example, my biggest weakness as an investor is probably the fact that I always sell too soon. That may sound strange, since I talk a lot about using the private equity mindset and have been known to hold stocks for years. But more often than not, no matter how long I held the shares or how much money I made, I will see the stock price continue to rise to levels I hadn't thought possible. However, because I bought the stocks at bargain levels things tend to work out in my favor anyway.

For years my favorite metric has been price to book value; however, over the past few years I have begun to use the enterprise value for non-financial companies. Tobias Carlisle and his excellent books Quantitative Value and Deep Value had a lot to do with my changing view on valuation ratios. I still use price to book, especially for financial stocks, but the EV/EBIT ratio has been a valuable addition to my arsenal.

I spent some time talking value with Tobias last week. He outlined his thinking on evaluating companies, telling me: "My favorite approach is always going to be the acquirer's multiple, which is operating earnings, EBIT operating earnings, on enterprise value. The reason is that I like to approach them the way a private equity firm or leveraged buyout firm would. Even though you can't see how the business is going to improve, or you can't see how the stock is going to go up, you can see that it is going to survive or it's likely to survive even a nuclear winter. I think in those instances, even though you don't see something good happening, my experience is that something good does happen, because management doesn't just sit there on their hands. If they do, then there are activist investors out there who are always looking to stir something up, get them to do something, pay some money out, or buy back some stock."

I sat down this morning and ran a quick screen to look for some companies that trade at very low EV/EBIT ratios but look like they can survive until something good does happen to cause the stock price to rise.

Gilead Sciences (GILD) is hardly a speculative biotech company flirting with the possibility of extinction, but the market appears to be pricing it that way. The company has $15 billion in sales and is a major player in the markets for HIV and Hepatitis C drugs. Investor concerns about slowing sales and what many view as a weak pipeline of new drugs have led to strong selling in the stock and it is down about 20% over the past year.

Management are looking to reverse course and have hired a new head of the oncology and hematology divisions and have said they are looking for M&A possibilities to add to their R&D pipeline. The stock is just 15% above a three-year low and is trading at an EV/EBOT multiple of just 5.5 right now. It probably will not be a smooth ride, but I suspect that investors who hold the stock for several years will eventually be able to sell at much higher multiples.

Home builder Lennar (LEN) has seen steady progress over the past few years, but investors don't seem to care. Fears of higher mortgage rates have also kept investors form embracing the builders. Lennar recently announced that it was buying WCI Communities to expand its presence in the Florida marketplace, which is one of the most active in the U.S. right now. It is also beginning to focus on the first time home buyer market, which is finally starting to show signs of life.

CEO Stuart Miller is pretty positive about the prospects for his company. In the most recent earnings release, he told investors: "We have consistently believed that the housing market is continuing its slow and steady recovery and we have crafted our operating strategies specifically to position our company to grow at a measured pace and to act opportunistically in these market conditions. With the anticipation of a new President focusing on accelerating economic growth, we believe that our fortified balance sheet, our diversified business model and our refined product offerings will continue to hold us in good stead in a high-growth economy, despite the potential of moderately rising interest rates over the next several years."

Lennar has an EV/EBT ratio of just 2.4, so it is one of the cheapest stocks in the nonfinancial universe right now. Patient investors should see outstanding long-term results.

Buying stocks at bargain valuations can help offset a lot of the other mistakes we might make as investors. If we buy right, then time and value should do most of the heavy lifting for us.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Tim Melvin had no positions in the stocks mentioned.

TAGS: Investing | U.S. Equity | Healthcare | Basic Materials | Industrials | Drug Approvals | How-to | Markets | Stocks

More from Healthcare

There Are Market Bright Spots, but I View the July Rally as a Head Fake

Bret Jensen
Aug 3, 2022 10:30 AM EDT

It's hard to see stock valuations rising when inflation remains high and the economy appears headed for a recession if it isn't in one already.

A Recession Appears Inevitable, but There Are Still Places to Invest

Bret Jensen
Jul 27, 2022 10:30 AM EDT

A few homebuilders and healthcare stocks seem likely to hold up better than most of the market in a recession.

Change Healthcare Continues to Knock on a Breakout Level

Bruce Kamich
Jul 25, 2022 11:25 AM EDT

The CHNG chart is at an interesting juncture.

The Healing Process Begins for Cano Health

Bruce Kamich
Jul 21, 2022 1:30 PM EDT

Here's how to approach CANO as the shares have made a bottom formation.

With HCA Healthcare, I'm Getting Healthy Indications

Bruce Kamich
Jul 21, 2022 9:20 AM EDT

The healthcare provider is set to report earnings Friday.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:24 AM EDT PETER TCHIR

    Jobs Report Reaction: Incredibly Strong, But Questions to Ask

    An incredibly strong July jobs report. Not only d...
  • 08:54 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The Secret to Dealing With FOMO
  • 03:51 PM EDT REAL MONEY

    AMD Second-Quarter Earnings Live Blog

    Real Money's Eric Jhonsa covers 's second-quarte...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login